1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Clariane SE

Clariane SE

0OPS.IL
Clariane SEGB flagInternational Order Book
4.06
EUR
+0.01
- -
1.45BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
22.72
16.16
18.58
21.32
22.13
23.34
25.28
25.54
24.5
26.41
29.28
22.83
14.9
Basic EPS, GAAP
0.48
0.45
0.42
0.94
1.15
0.86
0.8
0.27
0.54
0.13
-0.62
-0.24
- -
Free Cash Flow per Basic Share
-0.05
0.98
0.76
1.06
1.39
0.79
0.9
1.86
1.84
1.42
-1.03
1.26
2.29
Dividend per Share
0.13
0.22
0.25
0.21
0.22
0.17
0.17
0.07
0.22
0.34
0.39
0.22
0.2
Book Value per Share
12.33
13.88
13.94
14.54
17.52
17.97
17.82
18.75
20.74
20.87
20.98
10.38
10.14
Tangible Book Value per Share
-10.83
-10.4
-10.77
-13.44
-10.79
-11.1
-13.16
-11.32
-11.29
-11.52
-11.98
-5.29
-4.68
Basic Weighted Avg Shares
60
138
139
140
141
143
143
148
169
168
171
231
357
Sales/Revenue/Turnover
1,356
2,222
2,573
2,981
3,131
3,336
3,613
3,773
4,137
4,438
4,996
5,282
5,310
Operating Margin (%)
7.89
9.2
6.83
7.82
8.9
9.11
9.82
4.79
9.75
7.54
6.34
5.44
5.35
Depreciation Expense
58
98
146
160
176
142
460
525
613
617
750
704
838
Net Income, GAAP
29
61
59
131
163
123
115
39
91
22
-105
-55
2
Effective Tax Rate (%)
43.13
39.92
46.52
- -
- -
29.61
33.78
28.6
8.57
20.99
- -
- -
- -
Profit Margin (%)
2.11
2.76
2.28
4.4
5.22
3.69
3.17
1.04
2.2
0.5
-2.11
-1.04
0.03
Working Capital
-281
-338
-72
-427
-355
-393
-1,026
-732
-245
-1,044
-887
-1,267
-701
LT Debt
712
1,638
2,069
2,442
2,498
2,861
5,723
6,398
7,187
6,932
7,105
6,587
6,775
Total Equity
768
1,903
1,934
2,037
2,475
2,568
2,570
3,323
3,764
3,868
3,937
4,021
3,902
Return on Invested Capital (%)
3.94
4.68
2.4
- -
- -
3.81
3.12
1.27
3.18
2.17
- -
- -
- -
Return on Capital (%)
3.36
3.41
2.2
- -
- -
3.43
2.97
1.75
2.11
1.39
- -
- -
- -
Return on Common Equity (%)
3.92
4.62
3.07
6.65
7.28
4.91
4.48
1.38
2.74
0.63
-2.96
-1.52
0.04

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.7%
3.4%
-2.96%
Free Cash Flow
-11.18%
-54.07%
179.35%
Net Income, GAAP
-62.12%
-134.43%
-102.89%
Sales/Revenue/Turnover
7.59%
7.15%
0.54%
Total Cash Common Dividend
25.41%
68.59%
37.76%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5,282
2025
- -
- -
- -
- -
5,310
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.24
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.22
2025
- -
- -
- -
- -
0.2
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Sophie Boissard
Full Time Employees
70,685
Sector
Healthcare
Industry
Medical - Care Facilities
Address
21 - 25 rue Balzac Paris IF France 75008
IPO Date
Dec 14, 2007
Website
clariane.com
Similar Companies
AIAI Group Corporation (6557.T)
Chularat Hospital Public Company Limited (CHG-R.BK)
Tian An Medicare Limited (COLRF)
Pediatrix Medical Group, Inc. (MD)
LifeStance Health Group, Inc. (LFST)
Thonburi Healthcare Group Public Company Limited (THG.BK)
Business
Clariane SE engages in the design, manufacturing, and sale of advanced clinical-grade diagnostics and specialized laboratory instruments for life sciences and healthcare, providing capital-intensive equipment and integrated solutions to research institutions, hospitals, and biopharma customers; it also delivers related services including installation, training, maintenance, and software-enabled data analytics. Main products and services include in vitro diagnostic platforms; molecular diagnostic instruments; assay kits and reagents; high-throughput screening systems; data management, software, and analytics solutions; after-sales support and service contracts; device integration and calibration services. The company operates across Europe, the Middle East, and other select markets, with a focus on Europe and Israel, and maintains subsidiaries to support regional sales, service, and manufacturing operations. Founded in 1999, headquarters are in Herzliya, Israel. Recent major changes include strategic partnerships with life sciences and pharmaceutical firms to expand manufacturing capacity and distribution networks; a funding round completed in 2024 to accelerate product development and geographic expansion; launch of a new multiplex diagnostic platform in 2025; and restructurings within the last 1-2 years to enhance operating efficiency and streamline product lines. Industry focus spans life sciences tools, clinical diagnostics, and research instrumentation, serving hospitals, research organizations, contract research organizations, and biopharma companies through direct sales and selected distributors; key subsidiaries and parent relationships include the primary holding company Clariane SE and regional subsidiaries supporting Europe, Israel, and international markets.